°ª¦åÀ£Á{§ÉªvÀø«ü¤Þ (¤G)

ªí¡]¤»¡^¨Ï¥Î­°À£¾¯ªvÀø¡A¹ï¦P®É¦ñ¦³¨ä¥L¯e¯f¤§¦n¡BÃa¼vÅT
ARCH INTERN MED/VOL 157, NOV 24, 1997
¦X¨Ö¯e¯f ÃĪ«ªvÀø

³Ì¨Î¿ï¾ÜÃĪ«
²Ä¤@«¬¿}§¿¯f¨Ö³J¥Õ§¿: ACE inhibitors
¤ßŦ°IºÜ: ACE inhibitors Diuretics
¦Ñ¦~¿W¥ß¦¬ÁY©Ê°ª¦åÀ£: ACE inhibitors Ca++ Channel blockers¡]ªø®Ä«¬DHP¡^ Diuretics
¤ß¦Ù±ð¶ë ACE inhibitorsµù¡G¦X¨Ö¤ß°IºÜ £] Blockers ¡]«ünon-ISA¡^

¦³§U¯q¤§¿ï¾ÜÃĪ«
¤ßµ±µh £] Blockers Ca++ Channel blockers
¤ß©ÐÀW¯ß¡BÅÖºû²Ó°Ê £] Blockers Ca++ Channel blockers ¡]«ünon-DHP¡^
²Ä1¡B2«¬¿}§¿¯f¨Ö³J¥Õ§¿ ACE inhibitors¡]¸û¦n¡^ Ca++ Channel blockers
²Ä2«¬¿}§¿¯f ACEI ¡³µù Diuretics ¡]§C¾¯¶q¡^
¥»ºA©ÊŸ§Ý £] Blockers¡]«ünon-cardioselective¡^
¤ß°IºÜ ACE inhibitors Ca++ Channel blockers ¡]«üamlodipine, felodipine¡^ Carvedilol
¥Òª¬¸¢¤®¶i¯g £] Blockers
°¾ÀYµh £] Blockers Ca++ Channel blockers ¡]«ünon-DHP¡^
¤ß¦Ù±ð¶ë¡]µL¤ß°IºÜ¡^ Ca++ Channel blockers¡]«üDiltiagem, Verapamil¡^
°©½è²¨ÃP¯g Diuretics ¡]«üthiazides¡^
¤â³N«e°ª¦åÀ£ £] Blockers
ÄáÅ@¸¢ªÎ¤j¦å¯×²§±` £\ Blockers
µÇ°IºÜ¡]¤p¤ßµÇ¦åºÞ©Ê°ª¦åÀ£¨Ö¦Ù»ÄÓþ¡Ù3mg/dl¡^ ACE inhibitors

¥i¯à¤Ï¦Ó¦³®`¤§ÃĪ«¡]¡±¡Gªí¸T§Ò!¡^
¤ä®ðºÞ®ð³Ý £] Blockers¡±
©PÃä¦åºÞ¯e¯f £] Blockers
¼~Æ{¯g £] Blockers Central £\ agonists Reserpine¡±
²Ä1¡B2«¬¿}§¿¯f(µL¦X¨Ö¤ßŦ¯f¡BÄY­«°ª¦åÀ£) £] Blockers ¡³µù Diuretics ¡]µù«ü¤j¾¯¶q¡^
¦å¯×²§±` £] Blockers ¡]«ü«DISA¡^ Diuretics ¡]µù«ü¤j¾¯¶q¡^
µh­· Diuretics
²Ä¤G¡B¤T«×©Ð«Çªýº¢ £] Blockers¡± Ca++ Channel blockers ¡]«ünon DHP¡±¡^
¤ßŦ°IºÜ £] Blockers ¡]°£Carvedilol¡^ Ca++ Channel blockers ¡]°£amlodipine¤Îfelodipine¡^
Ãh¥¥ ACE inhibitors¡± Angiotension II antagonists¡±
µÇ¦åºÞ°ª¦åÀ£ ACE inhibitors Angiotension II antagonists
¨x¯f £\-methyldopa¡± Labetalol
µÇ°IºÜ Potassium sparing agents
»¡©ú¡GISA=Intrinsic Sympathomimetic activity , DHP=Dihydropyridines
¡³µù¡G¨ÌUK Prospective Diabetes study, ¦@1148¦W²Ä¤G«¬¿}§¿¯f¤§°ª¦åÀ£±wªÌ¡Aªø¹F¤K¦~°lÂܵo²{¡A¨Ï¥ÎACE§í¨î¾¯©Î£]ªýÂ_¾¯¦bªvÀø¤j¦åºÞ©Î·L¦åºÞ¯fÅܳ£¯àÀò±o¦n³B¡A¥Bµo²{¦åÀ£±±¨î¸ûÄYÂÔ²Õ¡]144/82mmHg¡^¤ñ¦åÀ£ºû«ù¦b154/87mmHg²Õ¡A¯à­°§C1/3¦º¤`²v¡A1/2¸£¤¤­·¤Î1/2·L¦åºÞ¯fÅÜ¡C

¹Ï¡]¤G¡^°ª¦åÀ£ÃĪ«¤§§@¥Î³¡¦ì¤Î¾÷Âà

»¡©ú¡Gºû«ù¦åÀ£¤§¥Í²z¾÷Âà«D±`½ÆÂø¡F¼s¸q¨¥¡A¦åÀ£¬°¤ß³Õ¥X¶q»P©PÃä¦åºÞªý¤O¤§²Õ¦X¡C°ª¦åÀ£ªvÀø¨Ã«D§¹¥þ¨Ì¿àÃĪ«¡A©|¶·°t¦X«DÃĪ«ªvÀø¡A§ïÅܥͬ¡§ÎºA¡CÃĪ«ªvÀø¡A½Ð¿í¦uÃĪ«¨Ï¥Î­ì«h¡C¹Ï" "ªí¿³¾Ä§@¥Î¡F" "ªí¥ÜªýÂ_
ACE§í¨î¾¯¡A¦b°ªµÇ¯À°ª¦åÀ£¬°³Ì¨ÎÃĪ«¡F§CÆQ¡B§C¾¯¶q§Q§¿¾¯¦X¨ÖACE§í¨î¾¯¡A¬°«Ü¦X¾A¤§¨Ö¥ÎÃĪ«¡A¦ýACE§í¨î¾¯¹ï¥¿±`©Î§CµÇ¯À°ª¦åÀ£¤]¦³®Ä¡C

ªí¡]¤K¡^­°À£Àø®Ä¤£¨Î¤§­ì¦]

 

ú@ °²©Ê°ª¦åÀ£¤§­ì¦]

•  ³æ¿W©Ê¶E©Ò°ª¦åÀ£

•  ¹ïªÎ­D¯f¤H¨Ï¥Î¸û¤p¤§À£¯ß±a¡C

úA ¹x©T©Ê°ª¦åÀ£¤§­ì¦]

•  ¥¼³Q¹îı¤§Äòµo©Ê°ª¦åÀ£ [µù¡GµÇ¦åºÞ¤Î¤º¤Àªc©Ê°ª¦åÀ£(µÇ¤W¸¢¥Ö½è½F¡B­ìµo©Ê adolsteronism¡Bpheochromocytoma ¡B¥Òª¬¸¢©Î°Æ¥Òª¬¸¢¯e¯f)¡B©Î¥D°Ê¯ß¯U¯¶]

•  ¹ïªvÀø¤§¶¶±q©Ê¤£¨Î

•  «ùÄò¨Ï¥Î³y¦¨¦åÀ£¤W¤É¤§ÃĪ«¡]¦p®øª¢¸Ñ¼öÂíµh¾¯¡B¤fªAÁ×¥¥ÃÄ¡B¥Ì¯ó¡B¥i«Ý¦]¡] codeine¡^¡BÃþ©T¾JªvÀø¡B¦w«D¥L©R¡C¨Ï¥Î¬õ¦å²y¥Í¦¨¯À¡]erythropoietin¡^¡BÀôÌUÆF¡]cyclosporins¡^¡B »óÂH½¤¦¬ÁY¾¯¡]§Y»ó¸Ñ¥R¦å¾¯¡ANasal decongestants¡^

•  Åé²G¹L¶q¡A°ª ¶u¶¼ ­¹¡A¶i¦æ©ÊµÇ¥\¯à¤£¥þ¡A§Q§¿¾¯¥Î¶q¤£¨¬

•  µLªk§ïµ½¥Í¬¡«¬ºA¡A¤j¶q¶¼°s¡B§l µÒ ¡AÅé­«¤W¤É

µù¡G¥Í¬¡§ÎºA¥¼§ïÅÜ¡BÃĪ«¾¯¶q¤£¨¬»P¤£¾A·í¤§ÃĪ«¨Ö¥Î¡A ±`¾É­P­°À£Àø®Ä¤£¨Î¡C

¹Ï¡]¤T¡^ ¶}©l­°¦åÀ£ªvÀø«á¤§°lÂܬyµ{

 

 

¶}©l­°¦åÀ£ÃĪ«ªvÀø

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

<

¦åÀ£¤w¹FªvÀø¥Ø¼Ð­È

 

 

¦b¥¿±`¾¯¶q¤U¤´¥¼¹F¥Ø¼Ð­È

 

µo¥Í°Æ§@¥Î

 

 

°ª¤Î¶W°ª«×¦MÀI

¤¤¤Î§C«×¦MÀI

 

 

•  ¦p¨S¦³¤ÏÀ³¡A¥Ñ¨ä¥L¤ÀÃþ¤¤´«ÃĩαħC¾¯¶q¨Ö¥Î¨ä¥LÃĪ«

•  ¦p¥u¦³³¡¥÷¤ÏÀ³¡A¥[¤J¨ä¥LÃþ§O¤§ÃĪ«¡F©Î§ï¥Î§C¾¯¶q¨Ö¥ÎÃĪ«

•  ¥[±j§ïµ½¥Í¬¡«¬ºA

 

•  ¥Ñ¨ä¥L¤ÀÃþ¤¤´«ÃÄ©Î

•  ­°§C¾¯¶q¤Î¥[¤J¨ä¥LÃþ§O¤§ÃĪ«

•  ¨C¤T­Ó¤ë°lÂܦåÀ£¤Î¦MÀI¦]¤l

•  ¥[±j§ïµ½¥Í¬¡«¬ºA

•  ¨C¤»­Ó¤ë°lÂܦåÀ£¤Î¦MÀI¦]¤l

•  ¥[±j§ïµ½¥Í¬¡«¬ºA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

¸Õ¹Ï´î¤Ö¨Ö¥ÎÃĪ«ªººØÃþ©Î¾¯¶q

 

 

Ãø¥H±±¨î¤§°ª¦åÀ£¡A¦A¥[²Ä¤TÃþÃĪ«

¡]­YµL¸T§Ò¡A¥²¥]¬A§Q§¿¾¯¦b¤º¡^

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

¦A½Õ¾ãÃĪ«¾¯¶q©Î¦A¼W¥[·sÃĪ½¦Ü±±¨î¨ì¥Ø¼Ð¦åÀ£¡A©ÎÂश°ª¦åÀ£±M®a

µù¡G 1.­YµL§Q§¿¾¯¤§¨Ï¥Î¸T§Ò¡AÀ³ÁקK¦P®É¦X¨Ö¨Ï¥Î¤TºØ°ª»ù­°À£¾¯¡C

2.µL¦X¨Ö¯g¤§²Ä¤G¯Å°ª¦åÀ£¥H¤W¡A¤j³¡¤À¶·¨Ï¥Î¨âºØÃĪ«²Õ¦X¡A±`¬°thiazideÃþ§Q§¿¾¯¦X¨ÖACE§í¨î¾¯¡B¦åºÞ±i¤O¯À«ú§Ü¾¯¡B£]ªýÂ_¾¯©Î¶tÂ÷¤lªýÂ_¾¯¡C